Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China
December 05 2019 - 6:55AM
Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today
announced that it is continuing to expand a previously announced
partnership agreement to jointly develop, promote and offer
translational studies and clinical trial solutions to biotech and
pharmaceutical companies with Genecast (Beijing) Biotechnology Co.
Ltd (“Genecast”) of the Peoples Republic of China (PRC). Genecast
is a leader in offering diagnostic products and services in the
field of oncology and providing a wide range of diagnostic services
to pharmaceutical and biotech companies in the PRC. Interpace is
sending members of its technical/scientific and business
development teams to China this week to begin the tech transfer
requirements to support over $3 million of recently secured new
business with global pharmaceutical companies.
Michael McCartney, Chief Commercial Officer of
Interpace Pharma Solutions commented, “We will be joining the
Genecast business development team in China to jointly promote our
capabilities of tumor profiling testing and clinical testing
services in China and will be traveling to Beijing, Suzhou and
Shanghai to meet with Genecast pharma customers who are in need of
Interpace Pharma Solutions’ services” Mr. McCartney also added “We
are thrilled to announce the addition of Gordon Vansant, Ph.D. a
highly regarded industry expert to our BD team. Dr. Vansant has
deep relationships and contacts in China to further strengthen and
expand our penetration in China and Asia and will lead our BD
efforts in the Southwest US, headquartered out of San Diego.”
Du Bo, Co-Founder and CEO of Genecast, said, “We
are excited that the partnership with Interpace Pharma Solutions is
already working and we believe will strengthen our capabilities to
provide our customers with high-quality, streamlined one-stop
testing services globally. Interpace Pharma Solutions development
is in line with our strategy of helping pharmaceutical and biotech
companies on a global basis accelerate their biomarker-driven drug
development and drive precision medicine forward.”
Jack Stover, President & CEO of Interpace
Biosciences commented, “We are pleased with the new business
already being booked as a result of our relationship with such a
high-quality partner as Genecast and we are pleased to have such an
experienced and successful executive as Dr. Vansant join our Pharma
Solutions BD team. We look forward to expanding our partnership
with Genecast as well as expanding our international capabilities
in Europe, Asia and elsewhere in the near future,” concluded
Stover.
About Interpace Biosciences
Interpace Biosciences is a leader in enabling
personalized medicine, offering specialized services along the
therapeutic value chain from early diagnosis and prognostic
planning to targeted therapeutic applications.
Interpace Pharma Solutions is a market leader in
providing pharmacogenomics testing, genotyping, and biorepository
services to the pharmaceutical and biotech industries. The
Biopharma Business also advances personalized medicine by
partnering with pharmaceutical, academic, and technology leaders to
effectively integrate pharmacogenomics into their drug development
and clinical trial programs with the goals of delivering safer,
more effective drugs to market more quickly, and improving patient
care.
Interpace Diagnostics is a fully integrated
commercial and bioinformatics business unit that provides
clinically useful molecular diagnostic tests, bioinformatics and
pathology services for evaluating risk of cancer by leveraging the
latest technology in personalized medicine for improved patient
diagnosis and management. Interpace has four commercialized
molecular tests and one test in a clinical evaluation process
(CEP).
For more information, please visit Interpace
Bioscience’s website at www.interpace.com.
Genecast (Beijing) Biotechnology Co.
Ltd.
Genecast is a leader in offering diagnostic
products & services in the field of oncology and providing a
wide range of diagnostic services to pharmaceutical and biotech
companies in the Peoples Republic of China (PRC). Genecast’s
laboratories have met all applicable standards for accreditation
including accreditation from the CAP and earned top marks in a
number of external quality assessments carried out by CAP, EMQN,
the Clinical Test Center of the National Health Commission of China
and Center of Clinical Laboratories of Shanghai.
Genecast has formed collaborations with more
than 20 pharmaceutical and biotech companies in providing
comprehensive pre-clinical and clinical testing services.
For more information, please visit Genecast’s
website at http://english.genecast.com.cn.
Media Contact:Dan ChenGenecast (Beijing)
Biotechnologychen.dan@genecast.com.cn
Forward Looking Statements on Behalf of
Interpace Biosciences
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company’s future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including “believes,” “estimates,” “anticipates,” “expects,”
“plans,” “projects,” “intends,” “potential,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company’s control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company’s actual results to be materially different from those
expressed or implied by any forward-looking statement.
Additionally, all forward-looking statements are subject to the
“Risk Factors” detailed from time to time in the Company’s most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and other SEC filings. Because of these and other risks,
uncertainties and assumptions, undue reliance should not be placed
on these forward-looking statements. In addition, these statements
speak only as of the date of this press release and, except as may
be required by law, the Company undertakes no obligation to revise
or update publicly any forward-looking statements for any
reason.
INTERPACE CONTACTS: Investor Relations Joseph
Green, Edison Group jgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024